Shown is the monthly plasma concentration of erythropoietin (Panel A) and hemoglobin (Panel B) after TARGT EPO implantation in 9 of the 10 patients (the erythropoietin concentration in Patient 7 ...
Recombinant human erythropoietin (rEpo) is neuroprotective in neonatal models of hypoxic-ischemic brain injury. However, the optimal rEpo dose, dosing interval, and number of doses for reducing brain ...
Please provide your email address to receive an email when new articles are posted on . There are currently four FDA (Food and Drug Administration) approved erythropoiesis stimulating agents (ESAs) ...
First Subjects Enrolled in Phase IIa Clinical Trial of EPODURE Biopumps to Treat Anemia in Patients with End-Stage Renal Disease on Dialysis MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jul. 17, ...
CINCINNATI, Ohio — Akebia Therapeutics on Tuesday said it started its first Phase I human study (pdf) of a pill meant to help create new red blood cells in anemia patients. The drug, AKB-6548, is an ...
My mother is on dialysis (4 hours, twice a week) since past nine months. She had frequent urine infections which was cured 3-4 months back. Since the beginning she is taking Eprex 4000 injection to ...
Dec. 2, 2005 -- The US Food and Drug Administration (FDA), Amgen Inc, and Ortho Biotech Clinical Affairs, LLC, have notified healthcare professionals via letter regarding revisions to the safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results